Skip to content
Search

Latest Stories

NHS drug costs in England rose by almost 8%

The total cost to NHS commissioners for medicines, appliances and medicines devices in 2022-23 was £19.2 billion

The NHS Business Services Authority (NHSBSA) has published the latest figures for prescribing costs in primary and secondary care in England.


The total cost to NHS commissioners for the issue of medicines, appliances, and medical devices in 2022-23 is estimated to be £19.2 billion excluding central rebates, an increase of 7.99% from £17.8 billion in 2021-22.

This is the second time in two years that NHS drug costs in England have increased by this size.

Data published by the NHSBSA in November 2022 showed that the total prescribing costs rose by 8 per cent in 2021/2022 (£17.8bn) compared with 2020/2021 (£16.4bn).

After a deduction of £674m for central rebates, the total cost is estimated to be £18.5 billion.

The central rebate figure includes rebates from arrangements NHSEI have agreed with pharmaceutical companies following successful negotiations to commission a variety of treatments both in the cancer drugs fund (CDF) and in routine commissioning. This includes treatments for both rare diseases and more common conditions.

Fifty per cent of total expenditure or £9.6 billion was spent on medications prescribed in primary care and dispensed in the community.

Commenting on these latest figures, Tase Oputu, Chair of RPS England Pharmacy Board said: “Medicines are a fundamental part of our health service, saving and enhancing the lives of millions of people every year.

“These figures highlight more than ever the vital role of pharmacists in medicines optimisation, reducing overprescribing and cutting medicines waste.

“At the same time, pharmacy teams must also be enabled to continue supporting the best use of medicines for patients and not feel pressured into focusing solely on cutting costs.

“The Government and NHS must ensure that local pharmacy leaders have the time and support to develop pharmacy services, working with colleagues across the system. The latest CQC State of Care report showed that this needs additional resources and shouldn’t be an afterthought.

“Investing in pharmacy services can deliver both better outcomes for patients and better value for taxpayers.”

In 2022/23, the total cost of medicines issued in hospitals was £9.45 billion, which accounts for 49.2% of total expenditure.

The total cost to NHS commissioners for medicines prescribed in hospitals and dispensed in the community was £93.6 million.

Drugs worth £32.4 million were prescribed by dentists and dispensed in the community while the total cost for medicines prescribed and dispensed in the Adult Secure Estate was £24.9 million.

The average costs per capita when using Net Ingredient Cost (NIC) for items dispensed in the community for medicines, appliances, and medical devices prescribed in England in 2022/23 across all settings was £349, an increase from £324 in 2021/22.

At £3.26 billion, the British National Formulary (BNF) Chapter 8 – Malignant Disease and Immunosuppression had the highest spend across all settings in 2022/23, accounting for  16.4% of the total spend.

Of this spend, £3.09 billion was for medicines issued and dispensed in hospitals, as shown by the NHSBSA data.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less